St. Mary's General Hospital is a 147-bed adult acute-care facility in Kitchener, Ontario, Canada serving Waterloo Region and surrounding area. St. Mary’s is the second-largest acute care hospital in the St. Joseph’s Health System. It is the site of the Regional Cardiac Care Centre, which opened in 2003.

There are 147 beds in St. Mary's General Hospital.

During the past decade, St. Mary's General Hospital conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 1 clinical trials were completed, i.e. on average, 7.1% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 1 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Mary's General Hospital" #1 sponsor was "Ottawa Heart Institute Research Corporation" with 4 trials, followed by "Hamilton Health Sciences Corporation" with 2 trials sponsored, "McMaster University" with 2 trials sponsored, "Population Health Research Institute" with 2 trials sponsored and "Ratika Parkash" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Mary's General Hospital" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 10 trials as a collaborator, "Cardiac Arrhythmia Network of Canada" with 3 trials as a collaborator, "Medtronic" with 3 trials as a collaborator, "Heart and Stroke Foundation of Canada" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 35 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "St. Mary's General Hospital" are "Atrial Fibrillation" (5 trials), "Heart Failure" (4 trials), "COVID-19" (2 trials), "Stroke" (2 trials) and "Atherosclerosis" (1 trials). Many other conditions were trialed in "St. Mary's General Hospital" in a lesser frequency.

Most popular intervention types in "St. Mary's General Hospital" are "Drug" (8 trials), "Device" (7 trials), "Other" (4 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Convalescent plasma" (2 trials), "ARB + DMX-200" (1 trials), "Acetylsalicylic acid" (1 trials), "Adaptive Servo Ventilation" (1 trials) and "Amoxicillin-clavulanate" (1 trials). Other intervention names were less common.

The vast majority of trials in "St. Mary's General Hospital" are 21 trials for "All" genders.

Currently, there are NaN active trials in "St. Mary's General Hospital". 1 are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in St. Mary's General Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in St. Mary's General Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".